

3 February 2021

Intuitive Investments Group plc

Proposed Investment in Evgen Pharma plc

Intuitive Investments Group plc (AIM: IIG) (“IIG”), a closed-end investment company focussed on the life sciences sector, announces an investment of £175,000 to acquire 2,187,500 million ordinary shares of Evgen Pharma plc (AIM:EVG) (“Evgen”) at a price of 8 pence per share (the “Investment”). The Investment is part of the fundraising announced by Evgen on 2 February 2021. The Investment is conditional upon, amongst other things, the resolutions being passed at Evgen’s forthcoming general meeting on 3 March 2021.

Evgen is a clinical stage drug development company developing sulforaphane-based medicines for the treatment of multiple diseases.

The Investment in Evgen is the Company's fourth investment following its IPO in mid-December 2020.

David Evans, Chairman of IIG, has a pre-existing interest of 145,000 ordinary shares in Evgen and accordingly did not participate in the Company’s decision to approve the Investment.

For further information, please contact:

Intuitive Investments Group plc

David Evans

Via Walbrook PR

Strand Hanson Limited – Nominated Adviser

James Harris / James Dance / James Bellman

+44 (0) 20 7409 3494

Turner Pope Investments (TPI) Ltd – Broker

Andrew Thacker / Zoe Alexander

+44 (0) 20 3657 0050

Walbrook PR Limited – Media & Investor Relations

Paul McManus

+44 (0)20 7933 8780 or intuitive@walbrookpr.com

+44 (0) 7980 541 893

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014.

About Intuitive Investments Group plc

The Company is a newly established investing company, seeking to provide investors with exposure to a portfolio concentrating on fast growing and/or high potential Life Sciences businesses operating predominantly in the UK, continental Europe and the US, utilising the Board’s experience and in particular that of the Chairman, David Evans, to seek to generate capital growth over the long term for shareholders.